TY - JOUR
T1 - Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer
AU - Block, Matthew S
AU - Charbonneau, Bridget
AU - Vierkant, Robert A
AU - Fogarty, Zachary
AU - Bamlet, William R
AU - Pharoah, Paul D P
AU - Rossing, Mary Anne
AU - Cramer, Daniel
AU - Pearce, Celeste Leigh
AU - Schildkraut, Joellen
AU - Menon, Usha
AU - Kjaer, Susanne K
AU - Levine, Douglas A
AU - Gronwald, Jacek
AU - Culver, Hoda Anton
AU - Whittemore, Alice S
AU - Karlan, Beth Y
AU - Lambrechts, Diether
AU - Wentzensen, Nicolas
AU - Kupryjanczyk, Jolanta
AU - Chang-Claude, Jenny
AU - Bandera, Elisa V
AU - Hogdall, Estrid
AU - Heitz, Florian
AU - Kaye, Stanley B
AU - Fasching, Peter A
AU - Campbell, Ian
AU - Goodman, Marc T
AU - Pejovic, Tanja
AU - Bean, Yukie T
AU - Hays, Laura E
AU - Lurie, Galina
AU - Eccles, Diana
AU - Hein, Alexander
AU - Beckmann, Matthias W
AU - Ekici, Arif B
AU - Paul, James
AU - Brown, Robert
AU - Flanagan, James M
AU - Harter, Philipp
AU - du Bois, Andreas
AU - Schwaab, Ira
AU - Hogdall, Claus K
AU - Lundvall, Lene
AU - Olson, Sara H
AU - Orlow, Irene
AU - Paddock, Lisa E
AU - Rudolph, Anja
AU - Eilber, Ursula
AU - Jensen, Allan
AU - Georgia Chenevix-Trench
N1 - ©2014 American Association for Cancer Research.
PY - 2014/7
Y1 - 2014/7
N2 - Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the key genetic determinants of inflammation and immunity that affect prognosis are not known. The nuclear factor-kB (NF-kB) transcription factor family plays an important role in many immune and inflammatory responses, including the response to cancer. We studied common inherited variation in 210 genes in the NF-kB family in 10,084 patients with invasive EOC (5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous) from the Ovarian Cancer Association Consortium. Associations between genotype and overall survival were assessed using Cox regression for all patients and by major histology, adjusting for known prognostic factors and correcting for multiple testing (threshold for statistical significance, P < 2.5 × 10-5). Results were statistically significant when assessed for patients of a single histology. Key associations were with caspase recruitment domain family, member 11 (CARD11) rs41324349 in patients with mucinous EOC [HR, 1.82; 95% confidence interval (CI), 1.41-2.35; P = 4.13 × 10-6] and tumor necrosis factor receptor superfamily, member 13B (TNFRSF13B) rs7501462 in patients with endometrioid EOC (HR, 0.68; 95% CI, 0.56-0.82; P = 2.33 × 10-5). Other associations of note included TNF receptor-associated factor 2 (TRAF2) rs17250239 in patients with high-grade serous EOC (HR, 0.84; 95% CI, 0.77-0.92; P = 6.49 ± 10-5) and phospholipase C, gamma 1 (PLCG1) rs11696662 in patients with clear cell EOC (HR, 0.43; 95% CI, 0.26-0.73; P = 4.56 × 10-4). These associations highlight the potential importance of genes associated with host inflammation and immunity in modulating clinical outcomes in distinct EOC histologies.
AB - Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the key genetic determinants of inflammation and immunity that affect prognosis are not known. The nuclear factor-kB (NF-kB) transcription factor family plays an important role in many immune and inflammatory responses, including the response to cancer. We studied common inherited variation in 210 genes in the NF-kB family in 10,084 patients with invasive EOC (5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous) from the Ovarian Cancer Association Consortium. Associations between genotype and overall survival were assessed using Cox regression for all patients and by major histology, adjusting for known prognostic factors and correcting for multiple testing (threshold for statistical significance, P < 2.5 × 10-5). Results were statistically significant when assessed for patients of a single histology. Key associations were with caspase recruitment domain family, member 11 (CARD11) rs41324349 in patients with mucinous EOC [HR, 1.82; 95% confidence interval (CI), 1.41-2.35; P = 4.13 × 10-6] and tumor necrosis factor receptor superfamily, member 13B (TNFRSF13B) rs7501462 in patients with endometrioid EOC (HR, 0.68; 95% CI, 0.56-0.82; P = 2.33 × 10-5). Other associations of note included TNF receptor-associated factor 2 (TRAF2) rs17250239 in patients with high-grade serous EOC (HR, 0.84; 95% CI, 0.77-0.92; P = 6.49 ± 10-5) and phospholipase C, gamma 1 (PLCG1) rs11696662 in patients with clear cell EOC (HR, 0.43; 95% CI, 0.26-0.73; P = 4.56 × 10-4). These associations highlight the potential importance of genes associated with host inflammation and immunity in modulating clinical outcomes in distinct EOC histologies.
U2 - 10.1158/1055-9965.EPI-13-0962
DO - 10.1158/1055-9965.EPI-13-0962
M3 - Letter
C2 - 24740199
SN - 1055-9965
VL - 23
SP - 1421
EP - 1427
JO - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
IS - 7
ER -